No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TWST Twist Bioscience
- 30.750
- -0.750-2.38%
Close Apr 24 16:00 ET
1.78BMarket Cap-8518P/E (TTM)
31.900High30.280Low1.40MVolume31.840Open31.500Pre Close43.07MTurnover2.46%Turnover RatioLossP/E (Static)57.82MShares43.21052wk High3.01P/B1.75BFloat Cap11.46052wk Low--Dividend TTM56.94MShs Float214.070Historical High--Div YieldTTM5.14%Amplitude11.460Historical Low30.712Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Insufficient Growth At Twist Bioscience Corporation (NASDAQ:TWST) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 6.2x Twist Bioscience Corporation (NASDAQ:TWST) is definitely a stock worth checking out, seeing as almost half of all the Biotechs compani
Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024
Company to host conference call at 4:30 p.m. ET Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today
Twist Bioscience Is Maintained at Overweight by Barclays
Twist Bioscience Is Maintained at Overweight by Barclays
Express News | Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $40
Twist Bioscience Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/10/2024 26.78% Barclays $45 → $40 Maintains Overweight 02/05/2024 36.29% Scotiabank $30 → $43 Maintains
Barclays Sticks to Their Buy Rating for Twist Bioscience (TWST)
Comments
Twist Bioscience's P/S ratio remains lower due to sub-par revenue outlook, indicating investor expectation of limited future growth. Shareholder pessimism around future revenue growth contributes to this lower ratio.
Twist Bioscience Corporation (NASDAQ:TWST) Stock Catapults 29% Though Its Price And Business Still Lag The IndustryTwist Bioscience's optimistic cash runway and manageable burn rate are noteworthy despite the need for vigilance as the firm grows. Its market cap also points to easy fundraising potential.
Despite Twist Bioscience's unprofitability, rapid revenue growth indicates positive prospects. However, persistent share price decline hints at capital raising issues. Investors should assess the firm's balance sheet, market conditions and specific risks.
News
$Twist Bioscience(TWST.US$ Twist Bioscience Announced An Antibody Discovery, Option And License Agreement With Bayer Of Up To $188M. Bayer Will Have The Option To License Antibodies Discovered Under The Collaboration
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg